Cargando…

The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study

Nationwide data on glycemic control, blood pressure (BP) control and lipid control in patients with newly diagnosed type 2 diabetes were vacant in China. The aim of this study was to assess the clinical outcomes for these patients. This is an observational prospective cohort study with 12 months of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Xiaoling, Hu, Dayi, Pan, Changyu, Li, Guangwei, Lu, Juming, Ji, Qiuhe, Su, Benli, Tian, Haoming, Qu, Shen, Weng, Jianping, Zhang, Danyi, Xu, Jie, Ji, Linong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531462/
https://www.ncbi.nlm.nih.gov/pubmed/31118445
http://dx.doi.org/10.1038/s41598-019-44169-4
_version_ 1783420838849019904
author Cai, Xiaoling
Hu, Dayi
Pan, Changyu
Li, Guangwei
Lu, Juming
Ji, Qiuhe
Su, Benli
Tian, Haoming
Qu, Shen
Weng, Jianping
Zhang, Danyi
Xu, Jie
Ji, Linong
author_facet Cai, Xiaoling
Hu, Dayi
Pan, Changyu
Li, Guangwei
Lu, Juming
Ji, Qiuhe
Su, Benli
Tian, Haoming
Qu, Shen
Weng, Jianping
Zhang, Danyi
Xu, Jie
Ji, Linong
author_sort Cai, Xiaoling
collection PubMed
description Nationwide data on glycemic control, blood pressure (BP) control and lipid control in patients with newly diagnosed type 2 diabetes were vacant in China. The aim of this study was to assess the clinical outcomes for these patients. This is an observational prospective cohort study with 12 months of follow up. Patients with a diagnosis of type 2 diabetes less than 6 months were enrolled. Hemoglobin A1c (HbA1c) levels, BP levels and lipid levels were collected at baseline and the follow-ups. This study was registered at www.clinicaltrials.gov (NCT01525693). A total of 5770 participants from 79 hospitals across six geographic regions of China were recruited. After 12 months of treatment, 68.5% of these patients achieved HbA1c <7.0%; 83.7% reached BP <140/90 mmHg; 48.2% met low density lipoprotein cholesterol (LDL-c) <2.6 mmol/L; and 29.5% of patients reached the combined three therapeutic targets. Compared to those patients with baseline HbA1c <7.0%, patients with baseline HbA1c ≥7.0% had higher failure rate to reach glycemic control (relative risk (RR) = 2.04, p < 0.001), BP control (RR = 1.21, p < 0.001) and LDL-c control (RR = 1.11, p < 0.001). Obese patients had higher possibilities of failure in glucose control (RR = 1.05, p = 0.004), BP control (RR = 1.62, p < 0.001) and lipid control (RR = 1.09, p = 0.001) than patients with normal weight. The active smokers were more likely to fail in glycemic control than non-smokers (RR = 1.06, p = 0.002), and patients with physical activities were less likely to fail in lipid control than patients without exercises (RR = 0.93, p = 0.008). This study outlined the burdens of glycemic control, blood pressure control, lipid control in newly diagnosed type 2 diabetic patients in China, identified gaps in the quality of care and risk-factor control and revealed the factors influencing these gaps.
format Online
Article
Text
id pubmed-6531462
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65314622019-05-30 The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study Cai, Xiaoling Hu, Dayi Pan, Changyu Li, Guangwei Lu, Juming Ji, Qiuhe Su, Benli Tian, Haoming Qu, Shen Weng, Jianping Zhang, Danyi Xu, Jie Ji, Linong Sci Rep Article Nationwide data on glycemic control, blood pressure (BP) control and lipid control in patients with newly diagnosed type 2 diabetes were vacant in China. The aim of this study was to assess the clinical outcomes for these patients. This is an observational prospective cohort study with 12 months of follow up. Patients with a diagnosis of type 2 diabetes less than 6 months were enrolled. Hemoglobin A1c (HbA1c) levels, BP levels and lipid levels were collected at baseline and the follow-ups. This study was registered at www.clinicaltrials.gov (NCT01525693). A total of 5770 participants from 79 hospitals across six geographic regions of China were recruited. After 12 months of treatment, 68.5% of these patients achieved HbA1c <7.0%; 83.7% reached BP <140/90 mmHg; 48.2% met low density lipoprotein cholesterol (LDL-c) <2.6 mmol/L; and 29.5% of patients reached the combined three therapeutic targets. Compared to those patients with baseline HbA1c <7.0%, patients with baseline HbA1c ≥7.0% had higher failure rate to reach glycemic control (relative risk (RR) = 2.04, p < 0.001), BP control (RR = 1.21, p < 0.001) and LDL-c control (RR = 1.11, p < 0.001). Obese patients had higher possibilities of failure in glucose control (RR = 1.05, p = 0.004), BP control (RR = 1.62, p < 0.001) and lipid control (RR = 1.09, p = 0.001) than patients with normal weight. The active smokers were more likely to fail in glycemic control than non-smokers (RR = 1.06, p = 0.002), and patients with physical activities were less likely to fail in lipid control than patients without exercises (RR = 0.93, p = 0.008). This study outlined the burdens of glycemic control, blood pressure control, lipid control in newly diagnosed type 2 diabetic patients in China, identified gaps in the quality of care and risk-factor control and revealed the factors influencing these gaps. Nature Publishing Group UK 2019-05-22 /pmc/articles/PMC6531462/ /pubmed/31118445 http://dx.doi.org/10.1038/s41598-019-44169-4 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Cai, Xiaoling
Hu, Dayi
Pan, Changyu
Li, Guangwei
Lu, Juming
Ji, Qiuhe
Su, Benli
Tian, Haoming
Qu, Shen
Weng, Jianping
Zhang, Danyi
Xu, Jie
Ji, Linong
The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
title The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
title_full The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
title_fullStr The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
title_full_unstemmed The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
title_short The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study
title_sort risk factors of glycemic control, blood pressure control, lipid control in chinese patients with newly diagnosed type 2 diabetes _ a nationwide prospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531462/
https://www.ncbi.nlm.nih.gov/pubmed/31118445
http://dx.doi.org/10.1038/s41598-019-44169-4
work_keys_str_mv AT caixiaoling theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT hudayi theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT panchangyu theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT liguangwei theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT lujuming theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT jiqiuhe theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT subenli theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT tianhaoming theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT qushen theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT wengjianping theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT zhangdanyi theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT xujie theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT jilinong theriskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT caixiaoling riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT hudayi riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT panchangyu riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT liguangwei riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT lujuming riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT jiqiuhe riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT subenli riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT tianhaoming riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT qushen riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT wengjianping riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT zhangdanyi riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT xujie riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy
AT jilinong riskfactorsofglycemiccontrolbloodpressurecontrollipidcontrolinchinesepatientswithnewlydiagnosedtype2diabetesanationwideprospectivecohortstudy